Select Publications
Conference Abstracts
2023, 'Abstract 4670: True bench-to-bedside science: An international pilot study modeling hard-to-cure pediatric cancers to prioritize therapeutic intervention', in Cancer Research, American Association for Cancer Research (AACR), Vol. 83, pp. 4670 - 4670, http://dx.doi.org/10.1158/1538-7445.am2023-4670
,2022, 'PRECISION MEDICINE REVEALS A HETEROGENOUS TUMOUR IMMUNE MICROENVIRONMENT IN PAEDIATRIC GLIOMAS', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 69, pp. S327 - S328, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859203901292&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', in CANCER SCIENCE, WILEY, Vol. 113, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778583800159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'De novo design of CRISPR-Cas13b enables efficient silencing of SARS-CoV-2 variants and tumour pathogenic RNAs with near single-base precision', in Pathology, Vol. 54, pp. S15 - S16
,2021, 'CBL0137 promotes CART-cell therapy against MLL-rearranged leukemia', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 11 - 12, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Targeting chromatin potently inhibits leukemia progression in MLL-rearranged leukemia models', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 15 - 15
,2021, 'Using BET inhibitors to potentiate CAR T-cell therapy for neuroblastoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 41 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000074&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Abstract 3044: The unexplored immune landscape of high-risk pediatric cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 81, pp. 3044 - 3044, http://dx.doi.org/10.1158/1538-7445.am2021-3044
,2021, 'The unexplored immune landscape of high-risk pediatric cancers.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263506379&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 23, pp. 40 - 41, http://dx.doi.org/10.1093/neuonc/noab090.163
,2021, 'TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 23, pp. 18 - 19, http://dx.doi.org/10.1093/neuonc/noab090.075
,2020, 'DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii289 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.065
,2020, 'DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii290 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.066
,2020, 'DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii292 - iii292, http://dx.doi.org/10.1093/neuonc/noaa222.076
,2020, 'COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 22, pp. 290 - 290, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 22, pp. 302 - 302, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Abstract A03: Prevalence and spectrum of germline mutations in children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. A03 - A03, http://dx.doi.org/10.1158/1538-7445.pedca19-a03
,2020, 'Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. A35 - A35, http://dx.doi.org/10.1158/1538-7445.pedca19-a35
,2020, 'Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. A52 - A52, http://dx.doi.org/10.1158/1538-7445.pedca19-a52
,2020, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-SY09-02
,2020, 'DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in Neuro-oncology, Vol. 22, pp. iii302 - iii302
,2019, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children and Adolescents with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S504 - S505, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458005162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 61 - 61, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Prevalence and spectrum of germline mutations in children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 42 - 43, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with highrisk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 70 - 71, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma', in Tumor Biology, American Association for Cancer Research, pp. 2884 - 2884, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-2884
,2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4741 - 4741, http://dx.doi.org/10.1158/1538-7445.am2019-4741
,2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3659
,2019, 'Establishment of patient-derived xenograft models for high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-2884
,2019, 'Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4741
,2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111
,2018, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 65, pp. S643 - S644, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000445195005221&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CO, Denver, Vol. 20, pp. 67 - 67, presented at 18th International Symposium on Pediatric Neuro-Oncology (ISPNO), CO, Denver, 30 June 2018 - 03 July 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000438339000180&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CO, Denver, Vol. 20, pp. 49 - 49, presented at 18th International Symposium on Pediatric Neuro-Oncology (ISPNO), CO, Denver, 30 June 2018 - 03 July 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000438339000097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'DIPG-01. TARGETING THE POLYAMINE PATHWAY AS A NOVEL THERAPEUTIC TREATMENT AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 20, pp. i49 - i49, http://dx.doi.org/10.1093/neuonc/noy059.095
,2018, 'EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 20, pp. i67 - i67, http://dx.doi.org/10.1093/neuonc/noy059.178
,2018, 'Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-137
,2018, 'Targeting the polyamine pathway as a novel therapeutic treatment against diffuse intrinsic pontine glioma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-4800
,2018, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, Vol. 78, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-LB-138
,2018, 'EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA', in Neuro-oncology, Vol. 20, pp. i67 - i67
,2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', in ESMO Open, Elsevier BV, Vol. 3, pp. A238 - A238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
,2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, SPAIN, Madrid, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, SPAIN, Madrid, 22 June 2017 - 25 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.10539
,2016, 'HG-20COMBINATION OF EPIGENETIC MODIFIERS CBL0137 AND PANOBINOSTAT IS HIGHLY POTENT IN VITRO AND IN VIVO FOR DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-oncology, Vol. 18, pp. iii51 - iii51
,2015, 'Selective and rapid killing of mixed lineage leukemia and CALM-AF10 leukemia by SM7, a novel small molecule identified by chemical library screening', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, FL, Fort Lauderdale, Vol. 76, presented at AACR Special Conference on Advances in Pediatric Cancer Research - From Mechanisms and Models to Treatment and Survivorship, FL, Fort Lauderdale, 09 November 2015 - 12 November 2015, http://dx.doi.org/10.1158/1538-7445.PEDCA15-B23
,2015, 'The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1611
,2015, 'The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-146
,2011, 'THE VALUE OF MONITORING FOR MRD AT LATE TIMEPOINTS IN PAEDIATRIC ALL TREATMENT', in PEDIATRIC BLOOD & CANCER, WILEY PERIODICALS, INC, Vol. 57, pp. 707 - 707, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295239600003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,